BioMS and Lilly discontinue dirucotide after Phase III trial fails
This article was originally published in Scrip
BioMS and Lilly have discontinued the development programme of their potential multiple sclerosis therapy dirucotide after it failed to meet the primary endpoint of a two-year Phase III trial in secondary progressive MS.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.